KALA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
1.7M
-4.5%
1.8M
-82.4%
10.2M
+41.2%
7.2M
-34.4%
11.0M
R&D
59.0K
-3.3%
61.0K
-83.3%
366.0K
-94.0%
6.1M
-1.7%
6.2M
SG&A
1.7M
-4.5%
1.7M
-82.3%
9.9M
+117.4%
4.5M
-2.3%
4.6M
Operating Income
-1721000
+4.5%
-1802000
+82.4%
-10225000
-41.2%
-7239000
+34.4%
-11028000
EBITDA
-1721000
+4.5%
-1802000
+67.3%
-5512000
+47.7%
-10533000
+3.9%
-10961000
Net Income
-1581000
+2.5%
-1621000
-336.3%
686.0K
+109.1%
-7564000
+32.2%
-11155000
EPS (Basic)
$-21.32
-15128.6%
$-0.14
-110.3%
$1.36
+102.5%
$-53.50
+37.5%
$-85.64
EPS (Diluted)
$-21.32
-15128.6%
$-0.14
-110.3%
$1.36
+102.5%
$-53.50
+37.5%
$-85.64
Shares (Diluted)
74.2K
-99.4%
11.9M
+2247.2%
505.9K
+259.2%
140.8K
+8.1%
130.3K
KALA BIO (KALA) โ€” Financials